80 related articles for article (PubMed ID: 3015704)
1. Safety of immune globulins in relation to HTLV-III.
FDA Drug Bull; 1986 Jun; 16(1):3. PubMed ID: 3015704
[TBL] [Abstract][Full Text] [Related]
2. Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1985 Jun; 34(25):373-5. PubMed ID: 2989677
[TBL] [Abstract][Full Text] [Related]
3. The incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis in recipients of plasma products.
Piszkiewicz D; Kingdon H; Lee ML; Hooper J
Dev Biol Stand; 1987; 67():327-31. PubMed ID: 2440745
[TBL] [Abstract][Full Text] [Related]
4. Acquired immune deficiency syndrome (AIDS)--recommendations of IMAP.
International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
IPPF Med Bull; 1986 Jun; 20(3):3-4. PubMed ID: 12268332
[TBL] [Abstract][Full Text] [Related]
5. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 May; 35(20):334-9. PubMed ID: 3010072
[TBL] [Abstract][Full Text] [Related]
6. AIDS epidemic sparks campaign to encourage condom use.
Contracept Technol Update; 1985 Dec; 6(12):161-3. PubMed ID: 12280299
[TBL] [Abstract][Full Text] [Related]
7. HTLV-III: the etiologic agent of AIDS.
Sarngadharan MG; DeVico AL; Bruch L; Schüpbach J; Gallo RC
Princess Takamatsu Symp; 1984; 15():301-8. PubMed ID: 6100648
[TBL] [Abstract][Full Text] [Related]
8. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
[TBL] [Abstract][Full Text] [Related]
9. Regulatory control of blood products in Canada.
Boucher DW; Furesz J
Dev Biol Stand; 1987; 67():221-8. PubMed ID: 3609478
[TBL] [Abstract][Full Text] [Related]
10. Assessment of screening as a preventive technology: the example of HTLV-III/LAV antibody testing.
Ory HW; Koplan JP; Allen JR
Isr J Med Sci; 1986; 22(7-8):524-8. PubMed ID: 3640749
[TBL] [Abstract][Full Text] [Related]
11. HTLV-3 infection and AIDS: risk of spread by heterosexual contact.
Craske J
IPPF Med Bull; 1986 Feb; 20(1):3-4. PubMed ID: 12267664
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation.
Adler R; Safadi R; Caraco Y; Rowe M; Etzioni A; Ashur Y; Shouval D
Hepatology; 1999 Apr; 29(4):1299-305. PubMed ID: 10094978
[TBL] [Abstract][Full Text] [Related]
13. Immunization of children infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. Recommendations of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services.
Ann Intern Med; 1987 Jan; 106(1):75-8. PubMed ID: 3024547
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.
Ghany MG; Ayola B; Villamil FG; Gish RG; Rojter S; Vierling JM; Lok AS
Hepatology; 1998 Jan; 27(1):213-22. PubMed ID: 9425940
[TBL] [Abstract][Full Text] [Related]
15. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan.
Lo KJ; Tsai YT; Lee SD; Yeh CL; Wang JY; Chiang BN; Wu TC; Yeh PS; Goudeau A; Coursaget P
Hepatogastroenterology; 1985 Apr; 32(2):65-8. PubMed ID: 3159639
[TBL] [Abstract][Full Text] [Related]
16. HTLV and immunosuppression.
Essex M; Kanki P; Allan J; Barin F; McLane MF; Lee TH; Kitchen L; Homma T; Malone G; Yokota T
Princess Takamatsu Symp; 1984; 15():309-18. PubMed ID: 6100649
[TBL] [Abstract][Full Text] [Related]
17. HTLV-III infection in Canada in 1985.
Neumann PW; Benning BJ; Robinson DG; Gilmore N; O'Shaughnessy MV
CMAJ; 1986 Sep; 135(5):477-80. PubMed ID: 3461870
[TBL] [Abstract][Full Text] [Related]
18. [The HTL IV virus: a new human retrovirus without pathogen protection against the HTLV III/LAV virus?].
Mboup S; Essex M; Kank P; Ndoye I; Barin F; Samba ; Boye CS; Ricard D; Denis F; Romet JL
Afr J Sex Transmi Dis; 1986 Oct; 2(2):81-4. PubMed ID: 12281131
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of human T-lymphotropic leukemia virus type III associated with the acquired immunodeficiency syndrome.
Wong-Staal F; Hahn BH; Shaw GM; Arya SK; Harper M; Gonda M; Gilden R; Ratner L; Starcich B; Okamoto T
Princess Takamatsu Symp; 1984; 15():291-300. PubMed ID: 6100646
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus.
Yarchoan R; Redfield RR; Broder S
J Clin Invest; 1986 Aug; 78(2):439-47. PubMed ID: 3016028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
